The end of KRAS, and other, cancers? A new way forward

Drug Discovery Today

Volumn 19, Issue 4, 2014, Pages 383-387

  Mallucci, Livio ^a   Wells, Valerie ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NEW YORK UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN E; DACTOLISIB; GALAPTIN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P53; RAPAMYCIN; SMALL NUCLEAR RNA; WORTMANNIN; GALECTIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL MEMBRANE; CELL STRESS; COLON CANCER; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; LUNG CANCER; NEOPLASM; NERVE SHEATH TUMOR; NONHUMAN; ONCOGENE K RAS; OXIDATIVE STRESS; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; METABOLISM;

ANIMALS; GALECTINS; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84899509467     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.11.018     Document Type: Short Survey

References (40)

1. C. Mascaux et al. The role of RAS oncogene in survival of patients with lung cancer Br. J. Cancer 92 2005 131 139
2. W. Pao et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med. 2 2005 e17
3. K.A. Cengel et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells Neoplasia 9 2007 341 348
4. E. Massarelli et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin. Cancer Res. 13 2007 2890 2896
5. N.T. Ihle et al. Mutations in phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance Cancer Res. 69 2009 143 150
6. S. Gysin et al. Therapeutic strategies for targeting Ras proteins Genes Cancer 2 2011 359 372
7. M. Malumbres, and M. Barbacid RAS oncogenes: the first 30 years Nat. Rev. Cancer 3 2003 459 465
8. K.D. Courtney et al. The PI3K pathway as drug target in human cancer J. Clin. Oncol. 28 2010 1075 1083
9. A.T. Baines et al. Inhibition of ras for cancer treatment; the search continues Future Med. Chem. 3 2011 1787 1808
10. C.A. Pratilas, and D.B. Solit Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response Clin. Cancer Res. 16 2010 3329 3334
11. K. Cichowski, and P.A. Jeanne Drug discovery: inhibitors that activate Nature 464 2010 358 359
12. A.D. Cox, and C.J. Der The Raf inhibitor paradox: unexpected consequences of targeted drugs Cancer Cell 17 2010 221 223
13. O.K. Mirzoeva et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition Cancer Res. 69 2009 565 572
14. M.L. Sos et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer Proc. Natl. Acad. Sci. U. S. A. 106 2009 18351 18356
15. R. Shaw, and L. Cantley PI(3)K and mTOR signaling controls tumor cell growth Nature 441 2006 424 430
16. N.E. Torbett et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition Biochem. J. 415 2008 97 110
17. J.A. Engelman et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat. Med. 14 2008 1351 1356
18. J. Luo et al. Principles of cancer therapy: oncogene and non-oncogene addiction Cell 136 2009 823 837
19. A.T. Shaw et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress Proc. Natl. Acad. Sci. U. S. A. 108 2011 8773 8778
20. T. De Raedt et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for Ras-driven tumors Cancer Cell 20 2011 400 413
21. R.B. Corcoran et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Cancer Cell 23 2013 121 128
22. M. Molina-Arcas et al. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3kinase in KRAS-mutant lung cancer Cancer Discov. 3 2013 548 563
23. E.A. Collisson et al. Preclinical systems to study the biodistribution of nanoparticle delivery in pancreatic ductal adenocarcinoma Cancer Res. 72 Suppl. 8 2012 Abstr. 2906
24. V. Wells, and L. Mallucci Identification of an autocrine negative growth factor: mouse-β-galactoside binding protein is a cytostatic factor and cell growth regulator Cell 64 1991 91 97
25. C. Blaser et al. β-Galactoside binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells Eur. J. Immunol. 28 1998 2311 2319
26. V. Wells /sb:authors> et al. Functional inhibition of PI3K by the βGBP molecule suppresses Ras-MAPK signaling to block cell proliferation Oncogene 26 2007 7709 7714
27. L. Mallucci et al. Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo Mol. Cancer Ther. 11 2012 1884 1893
28. Y. Samuels et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells Cancer Cell 7 2005 561 573
29. J.S. Fridman, and S.W. Lowe Control of apoptosis by p53 Oncogene 22 2003 9030 9040
30. C.J. Brown et al. Awakening guardian angels: drugging the p53 pathway Nat. Rev. Cancer 9 2009 862 873
31. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase-Akt pathway in human cancer Nat. Rev. Cancer 2 2002 489 501
32. M. Jhawer et al. PI3Kmutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Res. 68 2008 1953 1961
33. B. Vogelstein et al. Cancer genomic landscapes Science 339 2013 1546 1558
34. L. Mallucci et al. Turning cell cycle controller genes into cancer drugs. A role for an antiproliferative cytokine (βGBP) Biochem. Pharmacol. 66 2003 1563 1569
35. V. Wells, and L. Mallucci Phosphoinositide 3-kinase targeting by the β-galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death Breast Cancer Res. 11 2009 R2
36. Mallucci, L. and Wells, V. (2011) βGBP, Compositions Comprising βGBP, and Related Methods and Uses Thereof. United States Patent US 7994113
37. A. Young et al. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling Cancer Discov. 3 2013 112 123
38. + T cells to block their TCR-mediated ERK activity and proliferation Brain Behav. Immun. 23 2009 1028 1037
39. L. Mallucci, and V. Wells Alternative use of signaling by the βGBP cytokine in cell growth and cancer control R. Srivastava, Apoptosis, Cell Signaling and Human Diseases: Molecular Mechanisms Vol 1 2007 Humana Press NJ 203 216
40. R. Ravatn et al. Circumventing multidrug resistance in cancer by β-galactoside binding protein, an antiproliferative cytokine Cancer Res. 65 2005 1631 1634